Newsroom

Temple University Hospital (TUH) will conduct a multi-centered, randomized, Phase 3 research study to learn if the experimental drug recombinant Factor VIIa (rFVIIa), a protein that our body makes, can be used to decrease bleeding in the brain of patients who suffer sudden bleeding in the brain, also called intracerebral hemorrhage (ICH).

Bold initiative designed to transform the clinical research landscape by training, developing and mentoring new clinical investigators dedicated to increasing clinical trial diversity.

Record philanthropic investment in the Lewis Katz School of Medicine in FY22 continued to create access to Temple’s excellence in innovative education, pioneering research and inclusive patient care.